Pyxis Oncology, Inc. (PYXS)

Pharmaceutical Preparations · market cap $269M · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-02 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Pyxis Oncology (PYXS) is a small-cap clinical-stage oncology company with 44 employees and a ~$169M market cap, advancing PYX-201 through Phase 2 for advanced solid tumors. The company is in acute financial distress with only $5.8M in cash and an estimated runway of approximately 0.7 months, making near-term capital raising an existential necessity rather than a strategic option.

The catalyst path

2026-11-02 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
PYX-201	Phase 2	Advanced Solid Tumours

Price & technical context

3-month

-18.2%

6-month

+59.6%

12-month

+5.9%

52-wk range

$1.06–$5.34

vs 50-day MA

-26.5%

vs 200-day MA

+8.2%

Realized vol

137.3%

Max drawdown

-81.4%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for PYXS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.